Drug-Target Interaction

Drug-Target Interaction (DTI) refers to the physical or chemical binding between a drug molecule and its biological target, such as a protein or nucleic acid. This interaction is the fundamental mechanism of drug efficacy. According to 2025 research trends, deep learning models like BCM-DTI are revolutionizing this field by enabling efficient in silico screening. In the context of enterprise risk management, DTI prediction accuracy directly impacts the success rate of drug discovery and the overall Return on Investment (ROI). Failure to accurately predict DTI can lead to costly clinical trial failures. Companies must ensure DTI data---including molecular structures and biological assays--is managed under ISO 22301 standards to maintain R&D continuity and comply with GDPR Article 9 regarding sensitive health data.

The practical application of DTI in enterprise risk management follows three steps: First, establish a structured DTI database with standardized data---including molecular fragments, protein sequences, and experimental assays--ensuring data integrity and traceability. Second, deploy AI-driven prediction frameworks, such as BCM-DTI, to perform virtual screening, which significantly reduces the cost of wet-lab experimentation. Third, implement a validation and risk-grading mechanism to prioritize candidates for experimental verification. For example, a Taiwan-based pharmaceutical company implemented AI-driven DTI prediction, achieving a 40% increase in early-stage screening efficiency and a 25% reduction in toxicity-related failures. These improvements directly contribute to the company's Business Continuity Management (BCM) by stabilizing the R&D pipeline and optimizing resource allocation.

Taiwan enterprises face three primary challenges when implementing DTI prediction. First, data silos: many companies lack standardized digital formats for experimental data. The solution is to implement an ISO 27701-compliant data governance framework. Second, talent shortage: there is a critical need for professionals with dual expertise in pharmacology and AI. Companies should be closely closely monitored and encouraged to partner with academic institutions or international AI-drug discovery platforms. Third, regulatory compliance: as AI-driven drug discovery gains momentum, regulatory bodies like the FDA and Taiwan's TFDA are increasing scrutiny on model explainability. Companies must adopt Explainable AI (XAI) techniques to ensure every DTI prediction is transparent and verifiable. The recommended priority is: Data Governance (Months 1-6) → Talent Acquisition & Training (Months 6-12) → Model Deployment & Regulatory Alignment (Month 12+).

Winners Consulting Services Co., Ltd. specializes in Drug-Target Interaction for Taiwan enterprises, delivering compliant management systems within 90 days. Our AI Agent team can precisely identify risks in your DTI prediction models, ensuring your R&D data complies with GDPR and Taiwan's Personal Data Protection Act. Free consultation: https://winners.com.tw/contact